BioSpace News Archive

The Collaboration Will Leverage Innovative Technology Platforms to Help Pharma Companies Develop Drugs Faster, More Efficiently and With Higher Success Rates

Luis A. Fernandez, MD, FACS, is the new division chief, intra-abdominal transplantation at Loyola Medicine. Dr. Fernandez is a world-renowned transplant surgeon specializing in pancreas, liver, islet cell and renal transplantation.

Wuhan Neurophth Biotechnology Ltd., a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases, today announced the appointment of Qiutang Li, Ph.D., as Chief Scientific Officer

Pharvaris, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, today announced clinical data from its Phase 1 multiple-ascending-dose study demonstrating PHA121’s pharmacokinetics and tolerability

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced a presentation at the 2021 TGFβ for Immuno-Oncology Drug Development Summit.

Verana Health, a leader in transforming clinical data into actionable real-world evidence, today announced a research collaboration agreement with Janssen Research & Development, LLC (Janssen).

Agricor Laboratories and Botanacor Laboratories jointly announced that they are responding to rising demand for their state-certified marijuana testing (Agricor) and accredited testing of hemp biomass and hemp-derived CBD products (Botanacor) by staffing up and naming four new personnel.

VentureMed Group, Inc. (VentureMed), a privately-held medical device innovator, announced today that data from three studies evaluating the use of its FLEX Vessel Prep (VP) System were presented during the virtual Leipzig Interventional Course (LINC) 2021, held Jan. 25 to 29, and are now available on demand

UbiQD, Inc., a New Mexico-based advanced materials company, announced today that it has published the groundbreaking results of the first phase of its NASA-funded plant trials in the open-access Nature Research journal, “Communications Biology.”

NervGen remains on track to initiate its Phase 1 program for NVG-291 in healthy volunteers in Q1 2021 with plans to report top-line results from the single and multiple dose portion of the study in the second half of 2021.